The antibody treatments are permitted under FDA emergency use authorization.
The study involved nearly 1,400 Mayo Clinic patients, half of whom received the antibody treatment. Each patient was evaluated at 14, 21 and 28 days after treatment.
The treated group was hospitalized at consistently lower rates than the untreated group.
By Day 14, 1.3 percent of treated patients were hospitalized, versus 3.3 percent of untreated patients. Day 21 saw no change in the hospitalization rate of treated patients while the untreated group’s rate jumped to 4.2 percent. At the 28-day mark, 1.6 percent of the treated group was hospitalized, compared to 4.8 percent of the untreated group — a 60-70 percent relative reduction for those treated with the antibody combination.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
